How effective is yervoy versus other cancer treatments?

How does Yervoy stack up against other melanoma treatments?

Yervoy (ipilimumab) is an immune checkpoint inhibitor that works by blocking CTLA-4, a protein on T-cells that keeps them from attacking cancer cells. It was one of the first drugs to show long-term survival gains in advanced melanoma. Clinical trials show overall response rates around 10-15% when used alone, but those numbers eroding once patients receive PD-1 inhibitors such as Keytruda or Opdivo ahead of it. When combined with Opdivo, response rates climb to 50% or more in some studies, but side effects rise sharply too.

What happens if Yervoy is used before or after a PD-1 inhibitor?

Patients who receive Yervoy after a PD-1 inhibitor often show lower response rates than patients who lead with a PD-1 inhibitor. Data from real-world studies indicate that sequential therapy—PD-1 first, then Yervoy—still produces some benefit, but the 5-year survival rate stays below 30% in manysurveys. The 5-year survival rate of patients who receive PD-1 first then Yervoy is below 30% in many surveys. The 5-year survival rate of patients who receive PD-1 first then Yervoy is below 30% in many surveys.